School of Medicine
Showing 1-10 of 26 Results
Jerome and Daisy Low Gilbert Professor and Professor of Biochemistry
Current Research and Scholarly Interests Telomeres are nucleoprotein complexes that protect chromosome ends and shorten with cell division and aging. We are interested in how telomere shortening influences cancer, stem cell function, aging and human disease. Telomerase is a reverse transcriptase that synthesizes telomere repeats and is expressed in stem cells and in cancer. We have found that telomerase also regulates stem cells and we are pursuing the function of telomerase through diverse genetic and biochemical approaches.
Assistant Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly Interests The Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
Linda Boxer, MD, PhD
Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor in the School of Medicine
Current Research and Scholarly Interests Regulation of expression of oncogenes in normal and malignant hematologic cells.
Clinical Assistant Professor, Medicine - Hematology
Current Research and Scholarly Interests I aim to provide high quality care in a diverse patient practice. My clinic includes all types of hematologic disorders, ranging from anemia, clotting/bleeding disorders, and low blood counts to complex malignancies such as leukemia, myelodysplastic syndrome, myeloma, and lymphoma.
My research interests include the advancement of personalized genomic medicine and the development of targeted therapeutics for cancer therapy.
My goal is to combine the efficiency of a private office with the complex care expected of a tertiary institution like Stanford. I value your time and strive to maintain an on-schedule clinic.
Clinical Instructor, Medicine - Hematology
Current Research and Scholarly Interests I am interested in the characterization and therapeutic targeting of cancer stem cells in human malignancies. Specifically I have been investigating antibody-specific approaches to therapeutically target leukemic stem cells in acute myeloid leukemia as well as targeting of cancer cells in other hematologic malignancies. This work has led to the identification and development of a monoclonal antibody targeting the anti-phagocytic signal CD47 for the treatment of human malignancies.
Professor of Medicine (Hematology) at the Stanford University Medical Center
Current Research and Scholarly Interests My research integrates clinical care of patients with novel treatments for a variety of hematologic disorders. I see patients with a wide range of problems with a particular focus on chronic lymphocytic leukemia and multiple myeloma. I provide comprehensive consultative services as well as treatment for both the acute and chronic leukemias as well as non-malignant conditions such as clotting disorders and thrombocytopenia.
Lawrence Tim Goodnough
Professor of Pathology and of Medicine (Hematology) at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Goodnough has a long-standing interest in alternatives to blood therapy. This includes the concept of antologous blood predonation before elective surgery; acute normovolemic hermodicution;erythropoietic agents to stimulate red blood cell production; pharmacologic strategies to reduce blood loss; artificial oxygen carriers; and re-evaluation of the transfusion trigger. Publications: Goodnough LT: "Erythropoietin", In Scientific Basis of Transfusion Medicine (Anderson K and Ness P),WB Saunders Co, Phila. 1994;830-842. Lenes B, Goodnough LT: Educational aspects of transfusion medicine, In Quality Assurance in Transfusion Medicine: Conceptual, Serologic, and Microbiologic Aspects. (Rock G, Seghatchin MJ, eds.), CRC Press, Boca Raton, FCA, 1992;Ch 5:89-103. Goodnough LT, Geha AS: A new era in blood conservation (editorial). Ann Thor Surg 1991;51:703-704.99.Goodnough LT. Autologous blood donation and transfusion. In Technical Manual (Tyler V, ed) 13th Edition, American Association of Blood Banks, Bethesda, MD, 1999:111-126. Goodnough LT. Alternative strategies in platelet therapy. Transfusion Alternatives in Transfusion Medicine 1999;3:25-30. Goodnough LT. Platelet transfusion therapy. J Clin Apher 2001;16:43-48. Goodnough LT. Red cell support in the perioperative setting. In Rossi's Principles of Transfusion Medicine, 3rd Edition (Simon T, ed), Lippincott, Williams and Wilkins, Philadelphia, PA, 2002; 590-601. Goodnough LT. Book Review "Practical Transfusion Medicine" (Murphy MF, Pamphilon D, eds). Lancet 2001;58:251.145. Goodnough LT. Transfusion Medicine (Reply to Letter). N Engl J Med 2002;347:538-539.148. Goodnough LT. Autologous blood donation and transfusion. In Technical Manual (Brecher M, ed), 14th Edition, American Association of Blood Banks, Bethesda, MD, 2002; pp 105-126.149.Goodnough LT. Platelet and granulocyte antigens and antibodies. In Technical Manual (Brecher M, ed), 14th Edition, American Association of Blood Banks, Bethesda, MD, 2002; pp 341-360.171. Goodnough LT. Blood and blood conservation: A national perspective. 2003; J Cardiothor Vasc Anesth 2004; 18(5)65-115.
Associate Professor of Medicine (Hematology) at the Stanford University Medical Center
Current Research and Scholarly Interests My research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including: